PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Dermatolog Treat. Author manuscript; available in PMC 2013 August 1.
Published in final edited form as:
PMCID: PMC3679890
NIHMSID: NIHMS466229

How Psoriasis Patients Perceive, Obtain, and Use Biologic Agents: Survey from an Academic Medical Center

Abstract

The availability of new biologic agents for the treatment of psoriasis provides hope for improved quality of life outcomes. However, the way patients come to use biologics, potential barriers they encounter, and their attitudes towards using these medications are still not well studied. Here, we conducted a survey of 106 psoriasis patients at an academic medical center to discern patient attitudes towards biologics. We found that most patients learn of biologics through their physician and perform follow-up research using the Internet. Most patients did not find it difficult to make the decision to start a biologic. Difficulty in obtaining biologics was associated with age less than 55 (p=0.01), lower income level (p=0.007), and lack of insurance (p=0.04). Patients were found to have high satisfaction and compliance rates on biologics. Of patients who missed a dose of their biologic, this was mainly due to logistical reasons such as not having the medication or forgetting to take it, rather than being depressed or overwhelmed. Patients with lower income levels had increased cutbacks in personal expenses due to co-payments (p=0.001). Among respondents, the mean annual out of pocket expense for a biologic was $557.12 per year, with a range of $0 to $7,000.

Keywords: Psoriasis, biologics, education, barriers, cost, compliance

Introduction

Psoriasis is an inflammatory skin disease affecting approximately 2-3% of the population. Approximately one-third of these patients suffer from generalized psoriasis (1). Patients with psoriasis suffer from pruritic, inflammatory plaques with a chronic, remitting and relapsing disease course. Psoriasis tends to remain active throughout a patient’s lifetime or becomes gradually more widespread. Psoriasis is associated with a high degree of morbidity, and has a tremendous impact on the lives of patients, affecting them physically, psychologically, and socially, and often requires long-term systemic treatments.

Psoriasis can negatively affect a patient’s psychological, social, and occupational well-being, often to the point where their quality of life (QoL) decreases significantly (2). Studies have shown that psoriasis patients often experience psychological and social difficulties including poor self-esteem, embarrassment regarding their physical appearance, and feelings of stigma and shame (3). Patients suffering from psoriasis are more likely to be depressed when compared to the general population, which can lead to increased suicidal ideation (4). The frequently quoted study by Rapp et al(5) showed that patients with psoriasis suffer just as much disability and negative QOL impact as patients with other serious medical illnesses such as heart disease, diabetes, and cancer. Furthermore, psoriasis can create a negative impact in the workplace, as patients with psoriasis are more likely to miss work due to their psoriasis or due to treatment, and may be less productive at work (5).

The availability of new biologic treatments with targeted mechanisms of action has transformed the treatment landscape for psoriasis. Currently, five biologic medications are FDA approved for the treatment of psoriasis in the United States. These include the TNF-alpha antagonists etanercept, adalimumab, and infliximab; the IL12/23 inhibitor ustekinumab, and the T-cell inhibitor alefacept. Additionally, the TNF-alpha antagonist golimumab is approved for the treatment of psoriatic arthritis. Efalizumab, a T-cell inhibitor, was withdrawn from the U.S. market in April 2009 due to several case reports of progressive multifocal leukoencephalopathy. The increasing use of the biologic medications may reflect their generally high efficacy rates (6, 7), relatively good safety profiles (6), and demonstrated improvement on quality of life (8, 9). However, it is not well understood how patients come to learn about biologics as a treatment option, the logistical and financial obstacles they encounter in obtaining treatment, and their perceptions about treatment once started. We conducted a survey of psoriasis patients treated with biologics to address these questions.

Methods

Patient-directed questionnaire

An anonymous questionnaire was distributed to adult psoriasis patients at the UCSF Psoriasis Center who were identified as having been treated with one or more biologic agents. Questionnaires with identical content were distributed by mail, in person during clinic visits, and by email between October 2010 and February 2011. Potential subjects were informed of the goals of the survey and invited to participate on a voluntary basis. The response rate was 106/207=51.2%. The questionnaire consisted of 34 multiple-choice or free text questions (Table II). All research was approved by the institutional review board at UCSF.

Table II
Survey Responses

Statistical Analysis

Statistical analysis was performed using SAS software. Association testing was performed using chi-square and Fisher’s exact tests. To evaluate whether there was a collinear relationship between variables identified as significant by association testing, Spearman rank correlation coefficients and tolerance values from linear regression were used.

Results

Patient Population

One hundred and six patients responded to the survey. The demographics of our survey respondents are shown in Table I. The mean age of survey respondents was 43.4 years (SD 12.6) and the mean age of onset of their psoriasis was 23.4 years (SD 12.78). 59% of patients were male, and 41% were female. Psoriatic arthritis was diagnosed by a medical professional in 40% of patients. The majority of our patients were self identified as Caucasian (59%), or Asian/Pacific Islander(32%). This population was highly educated, as 86% had at least an undergraduate degree. With regard to household income, 8 % had income less than $15,000, 22% had income between $15,000-$60,000, and 69% had income of $60,000 or above. 93% of patients had health insurance. Nearly all respondents lived in an urban or suburban area (97%) with very few rural patients (3%). The survey respondents were highly experienced with use of biologic medications with 51% having used 2 or more biologics. The main biologics used by our population were etanercept (70%) and adalimumab (62%), with the remainder (alefacept, efalizumab, infliximab, ustekinumab, and golimumab) counting for less than 13% each.

Table I
Characteristics of the study population

Awareness, Education, and Decision Making

We asked survey respondents how they first learned of biologic agents, the types of further research they did, the ease of decision making, and their expectations regarding improvement when starting a biologic medication. The responses are shown in Table II. We found that most patients in our survey learned of biologics from a physician (74.5%) and that the vast majority of our patients did further research on their own (89.5%), primarily using the Internet (88.5%). Eighty-five percent of respondents stated the difficulty level in making the decision to start a biologic was easy to moderate. Nearly half the respondents, 47.7%, indicated that they expected significant or complete improvement from the biologic prior to starting the treatment.

Difficulties faced in obtaining biologic medication

We asked questions evaluating the difficulty level in obtaining biologic medications. Results are reported in Table II. For 81.5% of patients, the time interval from when the prescription was written for a biologic medication to the time of receiving the first injection was one month or less. Regarding opinions on difficulty level in obtaining biologic medications, 64.1% of patients stated this was “not difficult at all” to “minimally difficult”. The most commonly reported obstacle in obtaining biologic medications was “difficulty with insurance approval,” followed by “being too expensive,” and “problems with the pharmacy in filling the prescription.” On univariate analysis, difficulty in obtaining medications was associated with age less than 55 years (p=0.01), income level less than $100,000 (p=0.007), and lack of medical insurance (p=0.04) (Table III). Further analysis revealed that age and income level were independent risk factors, whereas lack of insurance was correlated with lower income. In addition, a sensitivity analysis of income levels showed that difficulty in obtaining biologics was not just associated with income less than $100,000, but also income less than $60,000 (p=0.030) and less than $40,000 (p=0.027). No association was found between difficulty in obtaining biologics and psoriatic arthritis status (p=0.206), gender (p=0.161), and education level (p=0.898) (Table III).

Table III
Evaluation of Characteristics Associated with Difficulty Obtaining Biologics, Worrying about Side Effects, Cutting Back on Personal Expenses, and Difficulty Deciding to Start a Biologic.

Patient satisfaction

The survey assessed patient expectations, satisfaction, and concerns. Results are also reported in Table II. As previously stated, 47.7% of patients expected “significant” or “complete” improvement of their psoriasis prior to starting the biologic. After starting a biologic, 75.2% rated their improvement as “significant” or “complete,” indicating a higher rate of improvement than originally expected. When asked about overall satisfaction with using biologics, 62.6% of respondents stated “very satisfied” with biologics. In our population we found that a large percentage had tried more than one biologic medication. The most common reason stated for stopping a previous biologic was “not as effective as desired,” followed by “experienced a side effect,” and then by “medication too expensive.”

When asked about how worried patients are that the biologic medication will cause an adverse effect, 57.5% of patients responded “not worried at all” or “minimally worried.” 42.5% responded “somewhat worried” or “extremely worried.” Statistical analysis showed a trend towards association between being worried about side effects and female gender (p=0.057), but not with education level (p=0.126) or number of educational sources consulted before deciding to start a biologic (p=0.859).

Financial considerations

Financial considerations were also a major target of this survey, given that biologic medications are expensive. Patients were asked if the co-pay for biologics has caused them to cut back on other personal and household expenses, and the majority of respondents (78.8%) stated that it has not. However, when respondents were stratified by annual income level above or below $100,000, those with income level below $100,000 were significantly more likely to cut back on their household expenses compared to those above $100,000, 32.7% vs 5.0%, (p=0.001, OR 9.24 [2.00-42.66]) (Table III). A sensitivity analysis showed that this difference persisted using an income level cutoff of $60,000 (p=0.033, OR 2.95 [1.06-8.17]), but not a cutoff of $40,000 (p=0.671, OR 1.31 [0.37-4.62]). The average for yearly out-of-pocket expense for current biologics was $557.12 dollars per year, with a median of $180, and range of $0 to $7,000.

Patient Compliance

Although patients were generally satisfied with using biologics, we examined their self-reported compliance with these medications. Patients were asked how frequently they miss a dose of their biologic. Two-thirds (66.6%) of the respondents reported that they “never” or “rarely” missed a dose, while 27.3% reported “sometimes” and 6.1% reported “often.” The most frequently cited reason for missing a biologic medication dose was “ran out of medication,” followed by “forgot,” “illness,” and “too busy.” Patients were also asked how often they intentionally changed the frequency of taking their biologic without consulting their physician. 14.1% of patients responded “sometimes” or “often.” Among those that ever changed the frequency, the most common reasons were “ran out of medication” or “psoriasis was under good control so I needed it less.” Less often was the change in frequency due to “concern about side effect,” “medication too expensive,” or patient being “depressed or overwhelmed.”

Opinion of Pharmaceutical Companies

Patients were also questioned about their opinion regarding pharmaceutical companies that produce the biologic medications. The majority of patients, 63.6%, stated that their opinion of these pharmaceutical companies was neutral. The majority of patients stated that they had not contacted the pharmaceutical companies directly for questions or other services, whereas 37.4% reported that they had. From respondents who had contacted pharmaceutical companies in the past, the majority stated that they were “somewhat satisfied” overall with the services provided, and the response was split evenly between respondents not satisfied and very satisfied.

Discussion

This survey explored how patients with psoriasis become aware of biologics, the barriers they face in obtaining these medications, their compliance, and their perceptions towards efficacy and potential adverse effects. The majority of the respondents with psoriasis had learned of biologic medications from their physicians, rather than from family or friends, or from advertisements. This suggests that physicians and other medical providers are the primary source of providing awareness about treatment options. It highlights the importance of offering these medications to patients who can benefit from these treatments, and to discuss the risks and benefits. Our study found that patients further researched biologic medications using the Internet as a tool. Therefore, it may be beneficial for dermatologists to provide patients with reliable online sources to obtain information on these medications, as patients are currently using this medium to obtain much of their information.

Most respondents found the decision to start a biologic medication “easy” or “moderate.” Even though these medications are more complex than prior treatments, if patients receive thorough information regarding these medications, the decision to start the medication may become easier. It should be noted, however, that this survey targeted individuals who had chosen to start a biologic medication and did not include those who learned about biologics and declined to use them. This may self-select for a population who had an easier time making this decision.

The majority of respondents had high expectations regarding improvement prior to starting biologics, and reported even higher satisfaction rates than expected after initiating therapy. The fact that patients tended to underestimate the degree of improvement on biologics suggest that perhaps the treating physicians undersold the potential benefits of biologics, or that patients may have downgraded their expectations due to previous treatment failures or the chronic severity of their disease. Overall, the majority of respondents were very satisfied with biologics. This is consistent with previous studies that had reported high satisfaction rates amongst patients using biologic therapies(10, 11). Thus, physicians should not hesitate to tell patients who are considering starting biologics that despite the risks of adverse effects or not responding to these medications, the great majority of patients on biologics are satisfied with their treatment.

Obtaining biologic medications was “not difficult” to “minimally difficult” for the majority of respondents. The majority had received their biologic medication within one month of the time the prescription was written. The most common difficulties encountered included problems with insurance companies and with the pharmacy filling the prescription. It must be noted that our center is specialized in the treatment of psoriasis, and there is dedicated staff devoted to advocating for patients and following up with insurance companies and pharmacy issues, which were the main two challenges faced by patients. Obtaining insurance approval for a patient for a biologic medication, and the logistics of obtaining the medication after approval can be challenging, and a knowledgeable support staff is imperative in helping with this process, especially in populations that have the most difficulty obtaining these medications. We found that the populations that had the most difficulty in obtaining biologics included younger patients (less than 55 years old), patients with lower income, and patients with no insurance. Because our data were anonymized, we were unable to explore the hypotheses that the association with younger age was due to those age 65 and older having Medicare coverage, and that the association with lower income was due to a less favorable insurance plan.

Our patient population had significant experience with biologic medications, with more than half having used more than one biologic. This patient population had very good compliance with biologic medications with the majority of patients reporting “never” or “rarely” missing a dose. The main reason for missing a dose of medication was running out of medication. This can be avoided with proper scheduling of patient visits and advance renewal of prescriptions. Other reasons stated for missing a dose included forgetting to take the medication, followed by difficult transport of medications due to vacations and travel. Since biologic medications consist of needle syringes and also require refrigeration, storage and transport of these medications is difficult while traveling. If patients wish to fly with these medications, storage in a hard-shell container with a cool pack and physician’s explanatory note is recommended. Other options include directly shipping the medication to the travel destination. Notably, only a small percentage of respondents cited depression and concerns about side effect as reasons for missing a dose of a biologic. This is in contrast to studies conducted with other therapies including topical and systemic therapies in which patient frustration and other psychosocial factors had significant influence on compliance(12).

Overall, respondents were not worried at all or minimally worried about possible adverse effects from their biologic medications. We explored whether certain demographic variables were associated with worrying about side effects and found a trend toward association with female gender, but not with number of educational sources consulted or education level.

Biologic medications are expensive as compared to previous psoriasis treatments(13-15). Studies have looked at populations who receive biologic medications and this population usually has a higher income level, and increased insurance coverage(16). The results of this survey were consistent with this finding as previously stated in the demographics the majority of patients in this study had higher incomes, were highly educated, and had health insurance coverage. The majority of our respondents stated that co-payments associated with biologic medications had not caused them to cut back on other personal or household expenses. As would be expected, respondents with higher income levels did not need to cut back on household expenses due to co-pays for biologic medications.

The majority of our respondents had never contacted the pharmaceutical companies that make their biologic medication, and the majority of respondents had a neutral opinion of the pharmaceutical companies. Of the minority who had contacted the pharmaceuticals the opinions were evenly split between dissatisfaction and satisfaction.

Study Limitations

First, since the response rate to our survey was 51.2%, there may have been a selection bias in those who chose to respond to the survey. These individuals might be more motivated to share their experiences with biologics due to good or bad experiences, be more educated, or be more facile with the Internet for those who chose to respond online. Second, the data from this survey was self-reported by respondents and is thus subject to recall bias. Third, our survey was administered to patients at a single site. The demographics of the population were such that the majority of respondents lived in an urban area, were highly educated, with increased income levels, and had health insurance. Results from this population may underestimate the burden of financial considerations regarding biologic medications. Finally, the survey was administered to patients who had received care at the UCSF Psoriasis Center. This is an academic center specializing in psoriasis, and there is dedicated staff to assist in the process of obtaining approval and renewals for biologic medications. Thus, the results of this study may not be generalizable non-academic sites or practices that do not have the same level of staff support.

Conclusion

Moderate to severe psoriasis is associated with much psychosocial co-morbidity and biologic medications are quite effective in treating psoriasis and increasing the quality of life of patients. We found that the majority of patients learned of biologic medications from their physician and conducted further research using primarily the Internet as a source. It is imperative to provide information on these therapies to eligible patients and provide support in the decision making process to start a biologic. We found that the groups who have the most trouble obtaining biologics are younger patients, those with lower income levels, and those with no medical insurance. Having a support staff to follow up with insurance companies and pharmacies may facilitate the process of obtaining biologic medications. Patients have high satisfaction rates and high compliance rates on biologic medications. When they do miss a dose it is often related to logistical reasons such as running out of medication, traveling, or forgetting to take medication, as opposed to psychosocial factors such as depression. It is important to ensure that patients have access to their biologic medications by scheduling follow-up visits well in advance of when medications run out, and also educating patients on how to travel with their biologic medications.

Acknowledgments

We thank the patients who participated in this survey as well as the staff at the UCSF Psoriasis Center for making this study possible. W.L. is supported by a grant from National Institute of Arthritis, Musculoskeletal and Skin Diseases (K08AR057763).

Footnotes

Declaration of Interest

The authors declare no conflicts of interest.

References

1. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826–50. [PubMed]
2. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav. 2000 Sep 15;70(5):567–71. [PubMed]
3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001 Mar;137(3):280–4. [PubMed]
4. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol. 1998 Nov;139(5):846–50. [PubMed]
5. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17(1):24–8. [PubMed]
6. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May;58(5):851–64. [PubMed]
7. Castelo-Soccio LVVA. Long-term efficacy of biologics in dermatology. Dermatologic therapy. 2009;22:22–33. [PMC free article] [PubMed]
8. Menter A. The effect of psoriasis on patients’ quality of life and improvements associated with alefacept therapy. J Cutan Med Surg. 2004 Dec;8(Suppl 2):20–5. [PubMed]
9. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007 May;156(5):945–50. [PubMed]
10. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg. 2004 Sep-Oct;8(5):310–20. [PubMed]
11. Jones-Caballero M, Unaeze J, Penas PF, Stern RS. Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch Dermatol. 2007 Jul;143(7):846–50. [PubMed]
12. Saghloul SGM. Objective Assessment of Compliance with Psoriasis Treatment. Arch Dermatol. 2004;140:408–14. [PubMed]
13. Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol. 2010 Jun;162(6):1324–9. [PubMed]
14. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009 Jun;160(6):1264–72. [PubMed]
15. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005 Mar;24(1):52–7. [PubMed]
16. Mahler R, Jackson C, Ijacu H. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg. 2009 Nov-Dec;13(6):283–93. [PubMed]